Anti-Coagulants - Eastern Europe

Eastern Europe

The Anti-Coagulants market in Eastern Europe is anticipated to witness a substantial growth in revenue, projected to reach US$314.10m by the year 2024.
Moreover, it is expected to exhibit a steady annual growth rate (CAGR 2024-2029) of 7.10%, ultimately leading to a market volume of US$442.70m by 2029.
When compared globally, United States is predicted to generate the highest revenue in the Anti-Coagulants market, with a staggering US$16,740.00m in 2024.
In Eastern Europe, the demand for anti-coagulants is steadily increasing due to the rising prevalence of cardiovascular diseases in the region.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Eastern Europe has been showing steady growth over the past few years, with a particular focus on the prevention of blood clots and strokes.

Customer preferences: Customers in Eastern Europe have been increasingly interested in preventative healthcare measures, leading to a rise in demand for anti-coagulants. Additionally, an aging population has also contributed to the growth of the market, as the risk of blood clots and strokes increases with age.

Trends in the market: One trend in the Anti-Coagulants market in Eastern Europe is the shift towards newer oral anticoagulants, which have a lower risk of bleeding compared to traditional anticoagulants. The market is also seeing an increase in the use of anticoagulants for the treatment of non-valvular atrial fibrillation, as well as for the prevention of venous thromboembolism.

Local special circumstances: Eastern Europe has a high prevalence of cardiovascular disease, which has contributed to the growth of the Anti-Coagulants market. Additionally, the region has a high incidence of venous thromboembolism, which has also driven demand for anti-coagulants.

Underlying macroeconomic factors: The Anti-Coagulants market in Eastern Europe is influenced by a number of macroeconomic factors, including government healthcare policies and regulations, as well as the availability of healthcare infrastructure and resources. The market is also affected by the overall economic climate in the region, which can impact the affordability and accessibility of healthcare services.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.